Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201303150 Principal Investigator: Tan, Benjamin
Title: A phase I/II study of X-82, an oral anti-VEGFR tyrosine kinase inhibitor, with everolimus for patients with pancreatic neuroendocrine tumors
Description: The purpose of this research study is to determine the best dose of a drug called X-82 when it is combined with everolimus, as well as to look at side effects that may occur when people receive this combination of drugs....MORE
___________________________________________________________________________________________________
 Number: 201210123 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study Combining MLN8237 with nab-Paclitaxel in Patients with Advanced Solid Malignancies
Description: The purpose of this research study is to discover the appropriate dose of the drugs MLN8237 and nab-paclitaxel when they are given together, as well as to look at any side effects that might occur and to evaluate how these drugs work together in patients with cancer....MORE
___________________________________________________________________________________________________
 Number: 201406030 Principal Investigator: Lockhart, A. Craig
Title: Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients with Advanced Solid Tumors or Relapsed/Refractory Lymphoma with Varying Degrees of Hepatic Function (C14019)
Description: The primary purpose of this study is to find out how blood levels may change when patients with cancer are given Alisertib (study drug) and also have reduced liver function. An additional purpose will be identifying side effects of Alisertib when given to patients with cancer who have reduced liver ...MORE
___________________________________________________________________________________________________
 Number: 201405129 Principal Investigator: Adkins, Douglas
Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Description: The purposes of this study are: to identify how much MGCD516 (the study drug) can safely be administered to patients with cancer, determine how much of the study drug is absorbed after taking MGCD516 capsules orally and how quickly the drug is cleared from the blood stream. The study will also look ...MORE
___________________________________________________________________________________________________
 Number: 201405068 Principal Investigator: Lockhart, A. Craig
Title: A Phase I, multi-center, non-randomized, open label, parallel-group study evaluating the pharmacokinetics and safety of regorafenib (BAY 73-4506) in cancer subjects with severe renal impairment compared to a control group
Description: The purpose of this study is to learn more about how the study drug, Regorafenib, is absorbed into the bloodstream and how the Regorafenib is broken down (metabolized) and removed (excreted) from the body in people with cancer and impaired (reduced) kidney function in comparison with people with can...MORE
___________________________________________________________________________________________________
 Number: 201405031 Principal Investigator: Lockhart, A. Craig
Title: An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
Description: The purpose of this research study is to find out what effects; good and/or bad, neratinib has in cancers with HER2 and HER3 mutations positive solid tumors. Neratinib blocks the function of HER2 and HER3....MORE
___________________________________________________________________________________________________
 Number: 201404117 Principal Investigator: Lockhart, A. Craig
Title: A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors (C15011)
Description: The purpose of part A of this study will be to determine how much MLN4924 (study drug) is in the body when a patient with cancer is also given either fluconazole or itraconazole and will also determine if there are any additional side effects when this combination of drugs are given together. The pu...MORE
___________________________________________________________________________________________________
 Number: 201403063 Principal Investigator: Govindan, Ramaswamy
Title: A Phase 1b/2, multi-center, uncontrolled, open-label, dose escalation study of refametinib (BAY 86-9766) in combination with regorafenib (BAY 73-4506) in patients with advanced or metastatic cancer (17064)
Description: The purpose of this research study is to determine if the combination of the study drugs, refametinib and regorafenib, is safe and if at what dose level patients with solid tumor cancers are able to tolerate the study drug. In addition to finding a safe and tolerate dose level for future research st...MORE
___________________________________________________________________________________________________
 Number: 201403006 Principal Investigator: Lockhart, A. Craig
Title: A Phase I study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients with Advanced solid Tumors (C31002)
Description: The purpose of this research study is to find out whether receiving MLN0128 causes any potential effects to the electrical activity of your heart. Your study doctor and Millennium will be looking at certain heart waves, called P,QRS and T waves, using an electrocardiogram (ECG)/Holter monitor. Of sp...MORE
___________________________________________________________________________________________________
 Number: 201308120 Principal Investigator: Lockhart, A. Craig
Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Description: The purpose of this study is to test the investigational drug MSB0010718C given in the treatment of solid tumors at different dose levels to see if it is safe and well tolerated when given once every two weeks. The study is also looking at how MSB0010718C is processed by the body....MORE
___________________________________________________________________________________________________
 Number: 201304130 Principal Investigator: Lockhart, A. Craig
Title: A Phase 1B, Open-Label, Dose-Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel, in Patients with Solid Tumors (C15010)
Description: The main purposes of this research study are to determine: • The discomforts and risks of MLN4924 in combination with docetaxel, paclitaxel and carboplatin, or gemcitabine • The highest dose of MLN4924 in combination with other standard treatments that can be given to patients without causing dis...MORE
___________________________________________________________________________________________________
 Number: 201204116 Principal Investigator: Lockhart, A. Craig
Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers
Description: The purpose of this research study is to learn whether a drug called vemurafenib is safe and effective in cancers caused by problems with the BRAF gene. Previous studies have shown that vemurafenib therapy can be beneficial in patients with a special type of metastatic melanoma that is caused by pro...MORE
___________________________________________________________________________________________________